🔎 Trials Near Me

Beranda › Kanker Kandung Kemih › Texas › San Antonio

Uji klinis Kanker Kandung Kemih di San Antonio, TX

13 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar San Antonio (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Menerima pesertaFase 1
  • South Texas Accelerated Research Therapeutics (START), San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Audie L Murphy VA Hospital, San Antonio
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Menerima pesertaFase 1
  • NEXT Oncology, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07090499

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Menerima pesertaFase 2
  • University of Texas Health Science Center at San Antonio, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07061964

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Menerima pesertaFase 1
  • Baptist M&S Imaging (Medical Center), San Antonio
  • USA Clinical Trials, San Antonio
  • MCOA Eye Associates, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07206225

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Menerima pesertaFase 1/2
  • START South Texas Accelerated Research Therapeutics, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05267626

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Menerima pesertaStudi observasional
  • The University of Texas Health Science Center at San Antonio, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Menerima pesertaFase 2
  • Urology San Antonio, PA dba USA Clinical Trials, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06567743

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Menerima pesertaFase 2
  • UT Health San Antonio, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05951179

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Menerima pesertaStudi observasional
  • University of Texas Health Science Center at San Antonio, San Antonio
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05825950

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • UT Health Mays Cancer Center, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626

IDOV-Immune for Advanced Solid Tumors

Menerima pesertaFase 1
  • South Texas Accelerated Research Therapeutics, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06910657

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • START San Antonio, San Antonio
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT07030257

Uji klinis Kanker Kandung Kemih di kota lain

Studi lain di San Antonio

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.